- 儀器無(wú)憂(yōu)網(wǎng)
- 服務(wù)中心
Nuvo Research
加拿大Nuvo Research Inc www.nuvoresearch.com
Nuvo Research Inc. , ( 宻西沙加， Mississauga) ，一專(zhuān)門(mén)研發(fā)可 涂布或穿透皮膚之 加拿大藥品開(kāi)發(fā)公司
Nuvo Research Inc. (馬克翰，Markham) 宣布公司因應(yīng)將完成的關(guān)鍵性第三期臨床成果，己網(wǎng)羅FDA專(zhuān)家群。公司的臨床測(cè)試在2005年底會(huì)完成，而初步成果預(yù)定會(huì)在2006年一月公布。為了處理公司預(yù)定2006年中期在FDA申請(qǐng)新藥上市許可作業(yè)(NDA)，公司已組成FDA顧問(wèn)委員會(huì)。公司這次臨床的測(cè)試藥物是Pennsaid(R)，這是一種外用非固醇類(lèi)消炎藥物，主要用來(lái)治療關(guān)節(jié)炎，目前在加拿大以及幾個(gè)歐洲國(guó)家都已在販賣(mài)。
Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario with manufacturing facilities located in Varennes, Quebec and Wanzleben, Germany, and a research and development facility in San Diego, California.
Nuvo is focused on developing targeted therapeutic products designed to produce minimal side effects. The Company develops drugs based on two technology platforms: transdermal drug delivery and immune system regulation.
Nuvo markets two products Pennsaid®, a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis and Oxoferin™, a topical wound healing agent.
Nuvo's primary focus is obtaining approval to market, and ultimately commercialize Pennsaid® in the U.S. market. Nuvo intends to leverage its transdermal drug delivery capabilities to create a portfolio of transdermal products targeting a variety of indications.
